StockNews.com Lowers Lipocine (NASDAQ:LPCN) to Hold

Lipocine (NASDAQ:LPCN) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Lipocine Trading Down 3.0 %

Shares of LPCN opened at $3.59 on Friday. The firm’s fifty day simple moving average is $5.78 and its two-hundred day simple moving average is $5.50. Lipocine has a 12 month low of $2.31 and a 12 month high of $11.79. The stock has a market capitalization of $19.20 million, a P/E ratio of -2.10 and a beta of 1.12.

Institutional Investors Weigh In On Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP acquired a new position in shares of Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine as of its most recent SEC filing. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.